Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical terzapide supplier giant prepares to release its latest quarterly report later this week. Experts are anticipating strong growth driven by the strong demand of Lilly's blockbuster treatments, particularly recent launches. However, there are also concerns about potential